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With increasing concerns regarding diminishing treatment options for gonorrhea, maintaining the efficacy
of currently used treatments and ensuring optimal Neisseria gonorrhoeae antimicrobial resistance surveillance
are of the utmost importance. Penicillin is still used to treat gonorrhea in some parts of the world. In this study,
we developed and validated a real-time PCR assay for the detection of penicillinase-producing N. gonorrhoeae
(PPNG) in noncultured clinical samples with the aim of enhancing penicillin resistance surveillance. The assay
(PPNG-PCR2) was designed to be an indirect marker of penicillinase activity, by targeting a region of sequence
predicted to be conserved across all N. gonorrhoeae plasmid types harboring the beta-lactamase gene while not
specifically targeting the actual beta-lactamase-encoding sequence. The assay was evaluated by using a total of
118 N. gonorrhoeae clinical isolates and 1,194 clinical specimens, including 239 N. gonorrhoeae-positive clinical
samples from which N. gonorrhoeae cells were isolated and for which phenotypic penicillinase results are
available. Overall, the PPNG-PCR2 assay provided 100% sensitivity and 98.7% specificity compared to bacte-
rial culture results for the detection of PPNG in clinical specimens. PPNG-PCR2 false-positive results,
presumably due to cross-reactions with unrelated bacterial species, were observed for up to 1.3% of clinical
samples but could be distinguished on the basis of high cycle threshold values. In tandem with phenotypic
surveillance, the PPNG-PCR2 assay has the potential to provide enhanced epidemiological surveillance of N.
gonorrhoeae penicillin resistance and is of particular relevance to regions where penicillin is still used to treat
gonorrhea.
The sexually transmitted disease gonorrhea remains a sig-
nificant public health challenge. Neisseria gonorrhoeae, the eti-
ological agent of gonorrhea, has developed resistance to mul-
tiple classes of antibiotics, including penicillins, tetracyclines,
macrolides, and quinolones, and the extended-spectrum ceph-
alosporins are now the mainstay of treatment in most settings
(10). However, there are still certain population “pockets”
where, owing to factors ranging from the limited use of anti-
microbials to geographical and microbial isolation from pop-
ulations harboring resistant strains, antimicrobial resistance
(AMR) is low and antibiotics such as penicillin can still be used
successfully in accordance with WHO guidelines (10). An ex-
ample of this is Australia’s Northern Territory, where, unlike
the other Australian mainland states, in vitro resistance to
penicillin is observed for 5% of the gonococci isolated from
the local population (9). Similarly, penicillin is still used to
treat gonorrhea in the French Overseas Territory of New Cale-
donia (13). Much as this comes as a welcome respite for local
public health officials, the history of AMR in N. gonorrhoeae
suggests that penicillin resistance will eventually emerge in
these populations unless there is a concerted application of
appropriate public health strategies, including the optimal sur-
veillance of AMR in gonococci.
In remote parts of the world, including regions of the Aus-
tralian Northern Territory, AMR surveillance poses significant
challenges. First, there are difficulties in obtaining viable gono-
coccal isolates from remote populations. Second, the com-
pleteness and representativeness of AMR data are gradually
being undermined by the increased use of nucleic acid ampli-
fication tests (NAATs) over bacterial culture techniques for
the diagnosis of gonorrhea. The viability of the bacterium is
not considered an issue when specimens are collected for
NAATs, and so there is often a limited possibility of pursuing
either phenotypic antibiotic susceptibility determinations or
typing following a NAAT-positive result (20). For these rea-
sons, there is now increased interest in the development of
systems for the non-culture-based detection of gonococcal
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AMR mechanisms. In this study, we develop and evaluate
real-time PCR for the detection of penicillinase-producing N.
gonorrhoeae (PPNG) using noncultured clinical samples.
MATERIALS AND METHODS
PPNG real-time PCR assays. The production of penicillinase in N. gonor-
rhoeae is encoded by plasmid-mediated beta-lactamase genes found in a number
of related gonococcal plasmid types that vary in size and are named on the basis
of the geographical location where they were first isolated. The three most
common plasmids are the Asian plasmid (7,426 bp), which is considered the
ancestral plasmid; the African plasmid (5,599 bp); and the Rio de Janeiro/
Toronto plasmid (5,154 bp). Other less common types are the Nimes (6,798 bp)
and New Zealand (9,309 bp) plasmids (3, 7, 8). In this study, two real-time assays
(PPNG-PCR1 and PPNG-PCR2) were designed by using Primer Express
software (Applied Biosystems Pty. Ltd., Australia), targeting sequence re-
gions at positions 671 to 774 and 937 to 1024, respectively, on the Asian
plasmid (GenBank accession number U20374). These regions fell within a larger
region of the sequence (nucleotides 605 to 1880 [Asian plasmid]) predicted to be
conserved across all the above-described plasmid types (8). Furthermore, these
sequences fell outside the TEM-1 beta-lactamase-encoding sequence (nucleo-
tides 6235 to 470 [Asian plasmid]) that is conserved across a diverse range of
bacterial species and the reported deletions of all other plasmid types. Given
that the gonococcal plasmids were originally thought to be acquired from
Haemophilus species (7), the GenBank Blast tool was used to aid primer and
probe selections to limit the sequence homology of the oligonucleotide tar-
gets with sequences of unrelated species.
The reaction mix for each assay consisted of 12.5 l of QuantiTect Probe PCR
master mix (Qiagen, Doncaster, Australia), 10.0 pmol each forward and reverse
primer (PPNG-F1 and PPNG-R1 for PPNG-PCR1 and PPNG-F2 and PPNG-R2
for PPNG-PCR2) (Table 1), 4.0 pmol probe (PPNG-TM1 for PPNG-PCR1 and
PPNG-TM2 for PPNG-PCR2) (Table 1), and 2.5 l of sample nucleic acid
extract in a final reaction mixture volume of 25.0 l. Reaction mixtures were
cycled on a Rotorgene 6000 real-time PCR instrument (Qiagen, Doncaster,
Australia) under the following parameters: an initial hold at 95°C for 15 min
followed by 45 cycles at 95°C for 15 s and 60°C for 60 s.
Isolates and clinical samples. The performances of the methods were assessed
in three stages. In stage 1, the sequence conservation and specificity of the
PPNG-PCR1 and PPNG-PCR2 assay targets were investigated by using a panel
of 118 N. gonorrhoeae isolates comprising both PPNG and non-PPNG strains. In
stage 2, specificity was further examined by using 652 specimens submitted for
sexual health screening that tested negative for N. gonorrhoeae by PCR. This
testing was performed to investigate cross-reactions with nongonococcal bacte-
rial species that may be present in these specimens. In stage 3, clinical sensitivity
and specificity for detecting PPNG were then investigated by using 542 speci-
mens submitted for sexual health screening that tested positive for N. gonor-
rhoeae by PCR. A subset of these samples (n  239) had also been tested by
bacterial culture, and the presence of penicillinase was assessed by standard
phenotypic methods. A summary of isolates and clinical samples used in this
study is provided in Table 2.
N. gonorrhoeae isolates. The 118 N. gonorrhoeae clinical isolates included 105
genetically diverse gonococci described in a previous study (19), comprising 58 N.
gonorrhoeae multiantigen sequence types (NG-MAST) (6) of mainly Australian
and Asian origins (years of isolation, 1988 to 2005), of which 10 isolates were
phenotypically identified as being PPNG isolates (isolates 1 to 10) (Table 3). The
remaining 13 gonococcal isolates were from Queensland, Australia (years of
isolation, 2001 to 2004), and were selected on the basis that they were PPNG
isolates (isolates 11 to 23) (Table 3) and included representatives of each of the
three main plasmid types, the Asian plasmid (n  8), the African plasmid (n 
4), and the Rio de Janeiro/Toronto plasmid (n  1), as determined by using a
previously described multiplex PCR for the differentiation of beta-lactamase
plasmids of N. gonorrhoeae (8).
N. gonorrhoeae-negative clinical specimens. Two panels of N. gonorrhoeae-
negative clinical samples were used in the study.
The first panel was comprised of DNA extracts of 192 specimens providing N.
gonorrhoeae-negative results using four different PCR assays as part of a previous
study (4). These specimens were submitted to Pathology Queensland (Path-
QLD) for N. gonorrhoeae screening in 2006 to 2007 and included 142 urogenital
specimens (42 urine specimens, 86 cervical swabs, and 14 vaginal swabs) and 50
throat swabs and had been stored at 70°C.
The second N. gonorrhoeae-negative specimen panel included 460 DNA ex-
tracts from Pathology, Royal Darwin Hospital (Path-RDH), Northern Territory,
Australia. These extracts provided negative results by an N. gonorrhoeae porA
pseudogene PCR method at Path-RDH and were derived from clinical samples
submitted to Path-RDH for N. gonorrhoeae testing during a 1-year period from
2008 to 2009. Samples from Path-RDH were extracted by using a MagNAPure
TABLE 1. Primers and probes used in the study
Primer or
probe Sequence (5–3)
a Positions
(bp)b
PPNG-F1 AATTCATTTAAAAAATCAGATTTTGAGCCTA 671–701
PPNG-R1 ACGAAAGTTACCAATGAAGATTTGC 774–750
PPNG-TM1 FAM-ATCTATTGCTATCGTTACCCGCTAGAAATACCCAG-BHQ 708–742
PPNG-F2 AGCTGTTCGTTTTTTACTACCAATCA 937–962
PPNG-R2 TGATTTAGTCGTTGAGGTTGAACAA 1024–1000
PPNG-TM2 FAM-AATTTAAAGAGTGAATAGTACGCCCACGCTTGA-BHQ 966–998
a FAM, 6-carboxyfluorescein; BHQ, black hole quencher.
b Asian plasmid (GenBank accession number U20374).
TABLE 2. Summary of isolates, specimens, and PPNG-PCR2
assay results
Specimen type and
no. of specimens
Penicillinase
phenotypea
Results of
PPNG-PCR2
assay
N. gonorrhoeae isolates
(total  118)
23 PPNG Positive
95 Non-PPNG Negative
N. gonorrhoeae-negative clinical
samples (total  652)
Queensland (n  192)
2 NA Positive
190 NA Negative
Northern Territory (n  460)
6 NA Positive
454 NA Negative
N. gonorrhoeae-positive clinical
samples (total  542)
Queensland (n  119)
3 PPNG Positive
22 Non-PPNG Negative
6 NA Positive
88 NA Negative
Northern Territory (n  423)
8 PPNG Positive
3 Non-PPNG Positive
203 Non-PPNG Negative
8 NA Positive
201 NA Negative
a The presence of penicillinase was assessed by phenotypic methods. NA, not
available.
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TABLE 3. All specimens providing positive results in the PPNG-PCR2 assayd
Specimen (type; yr of isolation) Phenotypea
PPNG-PCR2
result
(CT value)
porA PCR
result
(CT value)
CT value NG-MAST Plasmid typeb
N. gonorrhoeae
1 (Iso; 2004) PPNG Positive (21) Positive (25) 4 211
2 (Iso; 2004) PPNG Positive (25) Positive (29) 4 211
3 (Iso; 2004) PPNG Positive (26) Positive (28) 2 211
4 (Iso; 2005) PPNG Positive (31) Positive (34) 3 421
5 (Iso; 2005) PPNG Positive (26) Positive (30) 4 1496
6 (Iso; 2005) PPNG Positive (34) Positive (38) 4 1797
7 (Iso; 2005) PPNG Positive (24) Positive (27) 3 1919
8 (Iso; 2005) PPNG Positive (24) Positive (27) 3 1902
9 (Iso; 2005) PPNG Positive (31) Positive (34) 3 1921
10 (Iso; 2005) PPNG Positive (32) Positive (34) 2 1922
11 (Iso; 2002) PPNG Positive (13) Positive (17) 4 NP African
12 (Iso; 2004) PPNG Positive (14) Positive (18) 4 NP African
13 (Iso; 2004) PPNG Positive (15) Positive (18) 3 NP African
14 (Iso; 2004) PPNG Positive (15) Positive (19) 4 NP African
15 (Iso; 2001) PPNG Positive (12) Positive (15) 3 NP Asian
16 (Iso; 2002) PPNG Positive (13) Positive (17) 4 NP Asian
17 (Iso; 2002) PPNG Positive (14) Positive (16) 2 NP Asian
18 (Iso; 2004) PPNG Positive (14) Positive (17) 3 NP Asian
19 (Iso; 2004) PPNG Positive (14) Positive (17) 3 NP Asian
20 (Iso; 2002) PPNG Positive (15) Positive (16) 1 NP Asian
21 (Iso; 2001) PPNG Positive (15) Positive (18) 3 NP Asian
22 (Iso; 2004) PPNG Positive (18) Positive (20) 2 NP Asian
23 (Iso; 2004) PPNG Positive (13) Positive (17) 4 NP Rio/Toronto
N. gonorrhoeae-negative
clinical samples from
Queensland (Path-QLD)
24 (urine; 2007) NA Positive (33) Negative Not applicable
25 (urine; 2007) NA Positive (39) Negative Not applicable
N. gonorrhoeae-negative
clinical samples from the
Northern Territory
(Path-RDH)
26 (NA; 2008-2009) NA Positive (35) Negative Not applicable
27 (NA; 2008-2009) NA Positive (38) Negative Not applicable
28 (NA; 2008-2009) NA Positive (39) Negative Not applicable
29 (NA; 2008-2009) NA Positive (39) Negative Not applicable
30 (NA; 2008-2009) NA Positive (41) Negative Not applicable
31 (NA; 2008-2009) NA Positive (43) Negative Not applicable
N. gonorrhoeae-positive
clinical samples from
Queensland (Path-QLD)
32 (UrSw; 2004) PPNG Positive (17) Positive (21) 4 798
33 (UrSw; 2004) PPNG Positive (19) Positive (23) 4 New
34 (urine; 2003) NA Positive (22) Positive (25) 3 NP
35 (urine; 2003) NA Positive (22) Positive (26) 4 NP
36 (PnSw; 2003) NA Positive (22) Positive (26) 4 NP
37 (CxSw; 2003) PPNG Positive (24) Positive (30) 6 NP
38 (urine; 2006) NA Positive (25) Positive (29) 4 1797
39 (urine; 2003) NA Positive (28) Positive (33) 5 NP
40 (urine; 2003) NA Positive (43) Positive (29) 14 NP
N. gonorrhoeae-positive
clinical samples from the
Northern Territory
(Path-RDH)
41 (NA; 2008-2009) PPNG Positive (31) Positive (35) 4 758
42 (NA; 2008-2009) PPNG Positive (26) Positive (30) 4 1405
43 (NA; 2008-2009) NA Positive (32) Positive (37) 5 1405
44 (NA; 2008-2009) PPNG Positive (26) Positive (29) 3 1554
45 (NA; 2008-2009) PPNG Positive (21) Positive (26) 5 1691
46 (NA; 2008-2009) NA Positive (26) Positive (30) 4 1691
47 (NA; 2008-2009) NA Positive (25) Positive (29) 4 2996
Continued on following page
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instrument (Roche Diagnostics, Dee Why, Australia) according to the manufac-
turer’s instructions and stored at 70°C. Path-RDH samples were de-identified,
and further information, including sample site, was not available.
N. gonorrhoeae-positive clinical specimens. Two panels of N. gonorrhoeae-
positive clinical samples were used in the study.
The first panel was comprised of 119 DNA extracts from 100 urogenital
specimens (59 urine samples, 14 cervical swabs, 5 penile swabs, 6 vaginal swabs,
14 urethral swabs, and 2 swabs for which the genital site was not specified), 12
anal swabs, and 7 throat swabs submitted to Path-QLD from 2003 to 2007 and
which provided N. gonorrhoeae-positive PCR results in previous studies (4, 16,
18). Phenotypic penicillinase results were available for N. gonorrhoeae isolates
from 25 samples (3 urine samples, 4 anal swabs, 4 cervical swabs, 2 penile swabs,
1 vaginal swab, 10 urethral swabs, and 1 throat swab) and included 3 PPNG
strains and 22 isolates that did not produce penicillinase (non-PPNG). NG-
MAST data were available for 39 of these 119 samples (18).
The second panel was comprised of 423 DNA extracts from specimens sub-
mitted to Path-RDH for N. gonorrhoeae testing during a 1-year period from 2008
to 2009 and which provided positive results by N. gonorrhoeae porA pseudogene
PCR. N. gonorrhoeae strains were isolated from 214 of these samples by bacterial
culture at Path-RDH, 8 of which were phenotypically PPNG and 206 of which
were non-PPNG strains.
N. gonorrhoeae porA pseudogene PCR. All isolates and clinical samples pro-
viding positive results by PPNG-PCR were retested by a real-time PCR targeting
the N. gonorrhoeae porA pseudogene (porA monoplex) (4). Briefly, the porA PCR
method was performed by using the same basic reaction mix and cycling condi-
tions as those used for the PPNG-PCR methods except that the primers and
probe targeted the gonococcal porA pseudogene. The cycle threshold (CT) values
obtained by using the porA PCR were compared with those obtained by using the
PPNG-PCR methods. In addition, a 10-fold dilution series of DNA from a
PPNG strain was tested in the porA PCR and PPNG-PCR assays, and the results
were compared. The detection limit of each assay was determined as the lowest
concentration returning a positive reaction.
NG-MAST analysis. NG-MAST genotyping was performed on selected N.
gonorrhoeae-positive specimens as previously described (6, 18).
RESULTS
A summary of results for isolates and clinical samples is
provided in Table 2.
N. gonorrhoeae isolates. The PPNG-PCR1 and PPNG-PCR2
assays provided 100% agreement with the results of phenotypic
penicillinase testing for all 118 N. gonorrhoeae isolates for
which phenotypic penicillinase results were available: 95 iso-
lates were negative, and 23 isolates were positive (Table 3).
Lower CT values were observed for all 23 PPNG isolates in the
PPNG-PCR2 assay compared to those obtained using the porA
PCR (range of CT values, 1 to 4 cycles; mean, 3 cycles)
(Table 3). When 10-fold dilutions of PPNG DNA were tested,
the PPNG-PCR2 assay reliably detected the 104 dilution, and
the porA PCR reliably detected the 103 dilution, indicating
that the PPNG-PCR2 assay was approximately 10-fold-more
sensitive than porA PCR.
N. gonorrhoeae-negative clinical specimens. Of the 192 N.
gonorrhoeae-negative clinical samples from Path-QLD, 50
(26%) samples provided positive results in the PPNG-PCR1
assay (CT values ranged from 30 to 40 cycles; mean, 38 cycles),
2 two (1%) urine samples (specimens 24 and 25) (Table 3)
provided positive results in the PPNG-PCR2 assay (CT values
of 33 and 39 cycles). Evaluations of the PPNG-PCR1 assay
were discontinued on the basis of these results. When applied
to the 460 Path-RDW N. gonorrhoeae-negative clinical sam-
ples, 6 (1.3%) samples (specimens 26 to 31) (Table 3) provided
positive results in the PPNG-PCR2 assay (CT values ranged
from 35 to 43 cycles; mean, 39 cycles).
All eight N. gonorrhoeae-negative clinical samples providing
positive results in the PPNG-PCR2 assay were retested with
the porA PCR method, and negative results were obtained.
This confirms that these were false-positive results in the
PPNG-PCR2 assay.
N. gonorrhoeae-positive clinical specimens. (i) PPNG-PCR2
assay versus bacterial culture. Of the 239 N. gonorrhoeae-
positive samples for which bacterial cultures with phenotypic
penicillinase results were available (comprising samples from
both Queensland and the Northern Territory), 225 (94.1%)
samples were identified as being PPNG negative, and 11
(4.6%) samples were identified as being PPNG positive (spec-
imens 32, 33, 37, 41, 42, 44, 45, 50, 51, 52, and 53) (Table 3) by
both the PPNG-PCR2 assay and bacterial culture/phenotypic
analysis. The latter 11 samples comprised all PPNG-positive
clinical samples detected by bacterial culture used in this study.
Lower CT values were observed for these 11 specimens in the
PPNG-PCR2 assay than those obtained by using porA PCR
(range of CT values, 3 to 6 cycles; mean, 4 cycles)
TABLE 3—Continued
Specimen (type; yr of isolation) Phenotypea
PPNG-PCR2
result
(CT value)
porA PCR
result
(CT value)
CT value NG-MAST Plasmid typeb
48 (NA; 2008-2009) NA Positive (29) Positive (32) 4 2996
49 (NA; 2008-2009) NA Positive (22) Positive (24) 2 3782
50 (NA; 2008-2009) PPNG Positive (26) Positive (30) 4 3782
51 (NA; 2008-2009) PPNG Positive (22) Positive (26) 4 New
52 (NA; 2008-2009) PPNG Positive (22) Positive (26) 4 New
53 (NA; 2008-2009) PPNG Positive (25) Positive (31) 6 New
54 (NA; 2008-2009) NA Positive (28) Positive (31) 3 NAc
55 (NA; 2008-2009) NA Positive (31) Positive (36) 5 NAc
56 (NA; 2008-2009) Non-PPNG Positive (39) Positive (31) 8 NAc
57 (NA; 2008-2009) Non-PPNG Positive (40) Positive (31) 9 NAc
58 (NA; 2008-2009) Non-PPNG Positive (40) Positive (32) 8 NAc
59 (NA; 2008-2009) NA Positive (43) Positive (32) 11 NAc
a The presence of penicillinase was assessed by phenotypic methods.
b The plasmid type was available for the 13 Queensland isolates only.
c Amplification of the NG-MAST porB sequence, tbpB sequence, or both sequences was unsuccessful for these specimens.
d CxSw, cervical swab; PnSw, penile swab; UrSw, urethral swab; Iso, isolate; PPNG, penicillinase-producing N. gonorrhoeae; NA, not available; NP, not performed;
New, a matching sequence type could not be assigned by the NG-MAST database, and the isolate was considered to represent previously unidentified alleles or
combinations of alleles.
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(Table 3). A further three (1.3%) samples (specimens 56, 57,
and 58) (Table 3) were positive by the PPNG-PCR2 assay, yet
N. gonorrhoeae isolates from these samples were non-PPNG
isolates. These three specimens provided CT values that were
among the highest observed for the PPNG-PCR2 assay (39 to
40 cycles) (Table 3) and that were considerably higher than
those obtained by porA PCR (8 to 9 cycles) (Table 3).
(ii) Queensland samples. Of the 119 total N. gonorrhoeae-
positive clinical samples from Path-QLD, 110 (92.4%) were
negative and 9 (7.6%) were positive (specimens 32 to 40)
(Table 3) in the PPNG-PCR2 assay. The nine positive speci-
mens included all three Path-QLD specimens known to con-
tain PPNG strains on the basis of bacterial culture results. A
fourth positive sample (specimen 38) (Table 3) provided a
matching NG-MAST type with a PPNG strain (specimen 6)
(Table 3) isolated the preceding year in New South Wales,
Australia. Lower CT values were observed for the PPNG-
PCR2 assay than for the porA PCR for all but one of the nine
Path-QLD-positive specimens: specimen 40 provided a CT
value in the PPNG-PCR2 assay that was 14 cycles higher than
that of the porA PCR (Table 3).
(iii) Northern Territory samples. Of the 423 total N. gonor-
rhoeae-positive clinical samples from Path-RDH, 404 (95.5%)
were negative and 19 (4.5%) were positive (specimens 41 to
59) (Table 3) in the PPNG-PCR2 assay. The positive speci-
mens included all eight Path-RDH specimens known to con-
tain PPNG strains. These 19 positive samples were further
investigated by NG-MAST; 3 samples for which bacterial cul-
ture results were not available (specimens 43, 46, and 49)
(Table 3) provided matching NG-MAST types with samples
harboring PPNG strains (specimens 42, 45, and 50, respec-
tively) (Table 3). Four of the 19 positive specimens provided
higher CT values in the PPNG-PCR2 assay than in the porA
PCR (specimens 56 to 59) (Table 3). As discussed above,
non-PPNG strains were isolated from three of these samples,
whereas bacterial culture results were not available for the
remaining specimen.
DISCUSSION
With renewed concerns regarding the control of gonorrhea
arising from recent reports of multidrug-resistant gonococci
and the decreased in vitro susceptibility to both oral and in-
jectable extended-spectrum cephalosporins (2, 9, 10, 11, 12),
maintaining the efficacy of currently used treatments for gon-
orrhea is of the utmost importance. One facet of this is ensur-
ing optimal AMR surveillance, particularly in light of the in-
creased use of N. gonorrhoeae NAATs over bacterial culture
techniques and the decreasing availability of gonococcal iso-
lates for phenotypic testing. In this study, we successfully de-
veloped and validated a PCR assay for the detection PPNG in
noncultured clinical samples.
When designing the PPNG-PCR1 and PPNG-PCR2 assays,
we encountered a number of challenges: there was a need to (i)
identify sequence targets that were conserved across all vari-
ants of the gonococcal plasmids carrying the beta-lactamase
gene and (ii) limit the sequence homology of our oligonucle-
otide targets with those of other species. For assay designs, the
actual TEM-1 beta-lactamase gene would be an obvious choice
in terms of sequence conservation and also for being a direct
marker of the presence of the gene; however, this sequence is
conserved across a diverse range of bacterial species and there-
fore would clearly not be an optimal target in terms of PCR
specificity. For these reasons, we targeted conserved regions
outside the beta-lactamase gene on the gonococcal plasmids to
serve as indirect markers of penicillinase activity. Despite these
efforts, specificity problems were still evident in the PPNG-
PCR1 assay and, to a lesser extent, in the PPNG-PCR2 assay,
presumably due to the presence of the sequence targets in
unrelated bacterial species present in these samples. In partic-
ular, the PPNG-PCR1 assay provided poor specificity (74%)
when applied to a panel of N. gonorrhoeae PCR-negative sam-
ples, and evaluations of the PPNG-PCR1 assay were discon-
tinued on this basis. It should also be noted that both PPNG-
PCR1 and PPNG-PCR2 oligonucleotide sets provided a
100% match with a Neisseria meningitidis plasmid sequence
(GenBank accession number AF126482) that is nearly identical to
the gonococcal African plasmid. These assays therefore have
the potential to produce false-positive results for gonorrhea-
positive samples that also contain penicillinase-producing N.
meningitidis strains. However, this is not considered a limita-
tion given that N. meningitidis strains are infrequently found in
the human genital tract (18) and that N. meningitdis isolates
harboring this plasmid are rare (1).
Overall, the PPNG-PCR2 assay proved effective in detecting
PPNG in noncultured clinical samples, providing 100% sensi-
tivity and 98.7% specificity compared to bacterial culture re-
sults for the 239 clinical specimens tested using both methods.
Based on the results of the N. gonorrhoeae-negative samples
and the samples tested in parallel with bacterial cultures, it is
evident that the PPNG-PCR2 assay may provide false-positive
results in 1.0% to 1.3% of samples. However, decisions regard-
ing the treatment of gonorrhea are not made on a case-by-case
basis but are predetermined on the basis of antimicrobial sur-
veillance data to ensure a cure rate of 95% (21). Therefore, an
overestimation error of up to 1.3% could be considered ac-
ceptable when analyzing surveillance data obtained by using
the PPNG-PCR2 assay. On the other hand, the results suggest
that the PPNG-PCR2 false-positive results could otherwise be
omitted or lessened on the basis of cycle threshold (CT) values,
using either a set cutoff of approximately 35 cycles or a CT
value with the porA PCR. The gonococcal beta-lactamase plas-
mids are multicopy plasmids, whereas the porA pseudogene is
present as a single copy per gonococcal genome. Therefore,
one would expect the PPNG-PCR2 assay to have performance
characteristics at least comparable to those of the porA PCR
for PPNG strains. This is demonstrated by the fact that PPNG-
PCR2 had a 10-fold-better detection limit than did the porA
PCR and also had lower CT values than did the porA PCR for
all PPNG isolates and clinical samples known to contain
PPNG. It is for these reasons that the considerably delayed
PPNG-PCR2 CT values compared to those of the porA PCR
for samples 40 and 56 to 59 (8 to 14 cycles) (Table 3)
represent an obvious anomaly and suggest that the gonococci
in the samples were not PPNG. NG-MAST analysis provided
further evidence that four N. gonorrhoeae-positive samples
with positive CT values (and for which bacterial culture re-
sults were not available) did contain PPNG.
The use of either a cutoff of 35 cycles or positive CT values
for the Northern Territory N. gonorrhoeae-positive samples
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removes samples 56 to 59 (Table 3) from the positive results
and provides an overall PPNG rate of 3.6% (15/423) in this
cohort using the PPNG-PCR2 assay. This figure is consistent
with the results for the 214 samples used in the study from
which N. gonorrhoeae was isolated and tested phenotypically
for penicillinase at Path-RDH: 3.7% (8/214). However, these
data vary from previously reported phenotypic surveillance
rates for the Northern Territory for this period: N. gonorrhoeae
penicillin resistance rates were 3.9% and 4.2% in 2008 to 2009,
with PPNG rates of 2.9% and 2.5%, respectively (9). The basis
for this discrepancy is not clear and may be due to sampling;
however, this clearly warrants further investigation given that
the observed N. gonorrhoeae penicillin resistance rates in the
Northern Territory are sitting uneasily just below the WHO
threshold of 5.0%. In this context, it should also be noted that
chromosomally mediated penicillin resistance (CMPR) may
also occur and that reliance solely on the PPNG-PCR2 method
may underestimate true resistance levels. Thus, the PPNG-
PCR2 assay should be regarded as providing a baseline indi-
cation of penicillin resistance rather than the complete picture
but could nevertheless be used to show whether the WHO
threshold has been breached (such as what was shown for the
Queensland samples in this study). It is also for these reasons
that the PPNG-PCR2 assay should be considered a means of
enhancing phenotypic resistance surveillance rather than re-
placing it. Molecular methods for the detection of CMPR were
described elsewhere previously (5, 14) but have not been val-
idated for use on noncultured clinical samples. Furthermore,
CMPR is complex, involving the interaction of several mech-
anisms (increased efflux pump activity, reduced permeability,
and modification of the penicillin binding protein targets) and,
in our opinion, is not sufficiently elucidated to accurately pre-
dict phenotypes.
In conclusion, we have developed and evaluated a real-time
PCR assay for the detection of PPNG. To our knowledge, the
PPNG-PCR2 assay is the first assay of its kind to provide
definitive N. gonorrhoeae penicillin resistance data without the
use of cultured isolates. In tandem with phenotypic surveil-
lance, this assay has the potential to provide enhanced epide-
miological surveillance of N. gonorrhoeae penicillin resistance
and is of particular relevance to regions such as the Northern
Territory, Australia, where penicillin is still used to treat gon-
orrhea.
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